flutamide has been researched along with Ovarian Neoplasms in 7 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Flutamide has to be considered ineffective in patients extensively pretreated with chemotherapy, and it is not devoid of side-effects." | 2.67 | Phase II trial of flutamide in advanced ovarian cancer: an EORTC Gynaecological Cancer Cooperative Group study. ( Guastalla, JP; Rao, BR; Renard, J; Tumolo, S; van der Burg, ME; Vermorken, JB, 1994) |
| "Roles of androgens in testicular tumor development have been investigated in our previous studies using double-mutant mice lacking inhibins and carrying the null testicular feminization (tfm) mutation of the androgen receptor." | 1.32 | Sexually dimorphic roles of steroid hormone receptor signaling in gonadal tumorigenesis. ( Agno, JE; Burns, KH; Chen, L; Haupt, B; Korach, KS; Matzuk, MM; Ogbonna, SC, 2003) |
| "Treatment of ovarian cancer HEY cells with 500 nM 5alpha-dihydrotestosterone (DHT), but not estradiol-17beta or progesterone, for 60 h down-regulated the expression of mRNA for TGF-beta receptors I and II (TbetaR-I and TbetaR-II), betaglycan, and endoglin but had no effect on TGF-beta1 mRNA levels." | 1.31 | Down-regulation of transforming growth factor beta receptors by androgen in ovarian cancer cells. ( Brown, TJ; Evangelou, A; Jindal, SK; Letarte, M, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gruessner, C | 1 |
| Gruessner, A | 1 |
| Glaser, K | 1 |
| AbuShahin, N | 1 |
| Zhou, Y | 1 |
| Laughren, C | 1 |
| Wright, H | 1 |
| Pinkerton, S | 1 |
| Yi, X | 1 |
| Stoffer, J | 1 |
| Azodi, M | 1 |
| Zheng, W | 1 |
| Chambers, SK | 1 |
| Burns, KH | 1 |
| Agno, JE | 1 |
| Chen, L | 1 |
| Haupt, B | 1 |
| Ogbonna, SC | 1 |
| Korach, KS | 1 |
| Matzuk, MM | 1 |
| Wang, Y | 1 |
| Yang, J | 1 |
| Gao, Y | 1 |
| Dong, LJ | 1 |
| Liu, S | 1 |
| Yao, Z | 1 |
| van der Vange, N | 1 |
| Greggi, S | 1 |
| Burger, CW | 1 |
| Kenemans, P | 1 |
| Vermorken, JB | 2 |
| Tumolo, S | 1 |
| Rao, BR | 1 |
| van der Burg, ME | 1 |
| Guastalla, JP | 1 |
| Renard, J | 1 |
| Werner, A | 1 |
| Aichberger, A | 1 |
| Krebs, D | 1 |
| Evangelou, A | 1 |
| Jindal, SK | 1 |
| Brown, TJ | 1 |
| Letarte, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Phase IIA Study of the Effect of Flutamide (125 MG/DAY) Taken for 6 Weeks on Expression of Potential Biomarkers of Flutamide Action in the Ovaries of Women at Increased Risk for Ovarian Cancer[NCT00699907] | Phase 2 | 127 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"CSF-1 levels were measured by immunohistochemistry (IHC).~The modified H-Score assess extent of nuclear immunoreactivity applicable to steroid receptors.~The modified H-scores total range is 0-300. A lower modified H-score indicates weakly staining nuclei. A higher modified H-score indicated strongly staining nuclei.~This applies to all measures." (NCT00699907)
Timeframe: Surgery
| Intervention | Modified H-Score (Median) |
|---|---|
| Treatment Arm | 5 |
| High Risk Arm | 130 |
| Low Risk Arm | 50 |
CSF-1 levels were measured by immunohistochemistry (IHC). (NCT00699907)
Timeframe: Surgery
| Intervention | Histo-score (H-Score) (Median) |
|---|---|
| Treatment Arm | 0 |
| High Risk Arm | 50 |
| Low Risk Arm | 0 |
CSF-1 levels were measured by immunohistochemistry (IHC). (NCT00699907)
Timeframe: Surgery
| Intervention | Histo-score (H-Score) (Median) |
|---|---|
| Treatment Arm | 5 |
| High Risk Arm | 40 |
| Low Risk Arm | 35 |
CSF-1R levels were measured by immunohistochemistry (IHC). (NCT00699907)
Timeframe: Surgery
| Intervention | Histo-score (H-Score) (Median) |
|---|---|
| Treatment Arm | 15 |
| High Risk Arm | 160 |
| Low Risk Arm | 75 |
CSF-1R levels were measured by immunohistochemistry (IHC). (NCT00699907)
Timeframe: Surgery
| Intervention | Histo-score (H-Score) (Median) |
|---|---|
| Treatment Arm | 0 |
| High Risk Arm | 40 |
| Low Risk Arm | 20 |
CSF-1R levels were measured by immunohistochemistry (IHC). (NCT00699907)
Timeframe: Surgery
| Intervention | Histo-score (H-Score) (Median) |
|---|---|
| Treatment Arm | 20 |
| High Risk Arm | 40 |
| Low Risk Arm | 53 |
ErbB4 levels were measured by immunohistochemistry (IHC). (NCT00699907)
Timeframe: Surgery
| Intervention | Histo-score (H-Score) (Median) |
|---|---|
| Treatment Arm | 5 |
| High Risk Arm | 60 |
| Low Risk Arm | 10 |
ErbB4 levels were measured by immunohistochemistry (IHC). (NCT00699907)
Timeframe: Surgery
| Intervention | Histo-score (H-Score) (Median) |
|---|---|
| Treatment Arm | 0 |
| High Risk Arm | 55 |
| Low Risk Arm | 0 |
ErbB4 levels were measured by immunohistochemistry (IHC). (NCT00699907)
Timeframe: Surgery
| Intervention | Histo-score (H-Score) (Median) |
|---|---|
| Treatment Arm | 10 |
| High Risk Arm | 90 |
| Low Risk Arm | 30 |
2 trials available for flutamide and Ovarian Neoplasms
| Article | Year |
|---|---|
Flutamide and biomarkers in women at high risk for ovarian cancer: preclinical and clinical evidence.
Topics: Adult; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Area Under Curve; Biomarkers, | 2014 |
Phase II trial of flutamide in advanced ovarian cancer: an EORTC Gynaecological Cancer Cooperative Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Flutamide; Humans; Middle Aged; Ovari | 1994 |
5 other studies available for flutamide and Ovarian Neoplasms
| Article | Year |
|---|---|
Sexually dimorphic roles of steroid hormone receptor signaling in gonadal tumorigenesis.
Topics: Androgens; Animals; Body Weight; Cachexia; Cyclin D2; Cyclins; Estrogen Receptor alpha; Estrogen Rec | 2003 |
Reciprocal regulation of 5alpha-dihydrotestosterone, interleukin-6 and interleukin-8 during proliferation of epithelial ovarian carcinoma.
Topics: Androgen Receptor Antagonists; Carcinoma; Cell Line, Tumor; Cell Proliferation; Dihydrotestosterone; | 2007 |
Experience with hormonal therapy in advanced epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Carcinoma; Es | 1995 |
[Does interferon-alpha enhance the effect of tamoxifen-medroxyprogesterone acetate and hydroxyflutamide on in vitro tumor cells?].
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Cell Line; C | 1996 |
Down-regulation of transforming growth factor beta receptors by androgen in ovarian cancer cells.
Topics: Dihydrotestosterone; Down-Regulation; Female; Flutamide; Gene Expression Regulation; Humans; Ovarian | 2000 |